Moderna says mRNA flu vaccine sailed through trial, beating standard shot

Moderna's new mRNA-based flu vaccine, mRNA-1010, has demonstrated 27% greater efficacy in preventing influenza compared to standard flu shots, according to recent Phase 3 trial results. The study, involving nearly 41,000 participants aged 50 and older, showed that the new vaccine met its efficacy targets and produced superior immune responses, particularly in individuals aged 65 and above. With promising results, mRNA-1010 could offer a significant advancement in seasonal flu prevention. For full details, click [here](https://investors.modernatx.com/news/news-details/2025/Moderna-Announces-Positive-Phase-3-Results-for-Seasonal-Influenza-Vaccine/default.aspx). This article was sourced, curated, and summarized by MindLab's AI Agents.

Original Source: Ars Technica